Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00496379 · ClinicalTrials.gov registry record · Phase 2
ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases
A Phase 2 study, sponsored by Nancy Lin, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00496379: Clinical Trial Phase 2 study, sponsored by Nancy Lin, MD.
NCT00496379 is a Phase 2 study that was terminated before completion, run by Nancy Lin, MD. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00496379, a Phase 2 study, was terminated before completion, sponsored by Nancy Lin, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the effects (good and bad) of ZK219477(sagopilone) on participants and their cancer. ZK219477 is a chemotherapy drug that is thought to work by interfering with the ability of cancer cells to grow and divide. It is a part of a group of drugs called "epothilones" which appear to cause shrinkage of cancer in some patients with breast cancer. It is generally difficult for chemotherapy to enter the brain. However, it is believed that ZK219477 crosses into the brain. We are also studying whether an investigational MRI scan procedure may eventually help to predict which patients will benefit from ZK219477.
Primary Outcome
Objective response rate is defined as at least a 50 percent reduction in the Central Nervous system target lesion volume compared to the lesion volume at baseline.
Interventions
- DRUG ZK219477
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-07 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Why NCT00496379 stopped before completion
NCT00496379 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which ZK219477 is the first listed.
NCT00496379 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00496379 about?
NCT00496379 is a clinical study titled "ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases". The purpose of this research study is to determine the effects (good and bad) of ZK219477(sagopilone) on participants and their cancer. ZK219477 is a chemotherapy drug that is thought to work by interfering with the ability of cancer cells to grow and divide. It is a part of a group of drugs called ...
What is the current status of trial NCT00496379?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2007-07. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00496379?
The interventions under investigation include: ZK219477 (DRUG).
Who is sponsoring clinical trial NCT00496379?
This trial is sponsored by Nancy Lin, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00496379's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia